HIV gp41 Type O, Recombinant (Human Immunodeficiency Virus gp41 Type O)

HIV gp41 Type O, Recombinant (Human Immunodeficiency Virus gp41 Type O)
Item number Size Datasheet Manual SDS Delivery time Quantity Price
H6008-05.100 100 µg - -

1 - 19 business days

651.00€
 
gp41 is a glycoprotein non-covalently-bound to gp120, and provides the second step by which HIV... more
Product information "HIV gp41 Type O, Recombinant (Human Immunodeficiency Virus gp41 Type O)"
gp41 is a glycoprotein non-covalently-bound to gp120, and provides the second step by which HIV enters the cell. It is originally buried within the viral envelope, but, when gp120 binds to a CD4 receptor, gp120 changes its conformation, in such a way that the gp41 helps to initiate the process of membrane fusion between virus and cell. Source: Recombinant corresponding to HIV gp41 type O antigen fused to beta-galactosidase expressed in E. coli. Applications: Suitable for use in ELISA, Lateral Flow and Western Blot. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Supplier: United States Biological
Supplier-Nr: H6008-05

Properties

Application: ELISA, WB, Lateral Flow
Conjugate: No
Format: Highly Purified

Database Information

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "HIV gp41 Type O, Recombinant (Human Immunodeficiency Virus gp41 Type O)"
Write a review
or to review a product.
Information about the product reference will follow. more
Viewed